Study Provides Real-World Evidence for Inflammatory DED

Carolina L. Mercado, MD, and colleagues presented data from the American Academy of Ophthalmology IRIS (Intelligent Research in Sight) Registry linked to pharmacy claims data sourced from the Komodo Health Research Dataset.

By: Julie Greenbaum, editor

Ophthalmology Management April 10, 2026 Vol 30, Issue ASCRS 2026

Clinical Report: Study Provides Real-World Evidence for Inflammatory DED

Overview

A large cohort study of 143,005 patients with dry eye disease (DED) revealed significant comorbidities and underutilization of diagnostic testing. The findings underscore the need for improved management strategies in DED care.

Background

Dry eye disease (DED) is a prevalent condition that can significantly impact patients' quality of life. Understanding the real-world characteristics and treatment patterns of DED patients is crucial for developing effective management strategies. This study provides valuable insights into the demographics, comorbidities, and treatment approaches for DED in a diverse patient population.

Data Highlights

{'additional_demographics': 'Include breakdown of racial and ethnic diversity beyond just White patients.'}

Key Findings

{'additional_comorbidities': 'Mention other ocular comorbidities like age-related macular degeneration and diabetic retinopathy.'}

Clinical Implications

{'strategies': 'Suggest specific interventions or guidelines for clinicians to enhance DED management.'}

Conclusion

This real-world evidence highlights the complexity of managing DED and the need for enhanced diagnostic practices. Addressing these gaps can lead to better patient outcomes and more effective treatment strategies.

PentaVision

Ophthalmology Management